Open-label, Non-controlled Study of Lokivetmab in Atopic Dogs in Brazil

Abstract Background The subcutaneous injection of lokivetmab at day zero at the labeled dose range of 2mg/kg was evaluated in 106 dogs recruited from two private clinics in the State of São Paulo, Brazil. The objective of this 30-day open-label, non-controlled study was to evaluate the level of improvement in cases of canine Atopic Dermatitis (cAD) using the Canine atopic dermatitis extent and severity index (CADESI-4), Visual analogue scale (VAS) of pruritus, the incidence of adverse events, and owner’s perception of the treatment response by Global assessment of efficacy (OGATE). Results Baseline mean VAS of pruritus was 7.75 (median = 7), decreasing to 3.86 (median = 2) at day 2 ( p < 0.001). CADESI-4 scores decreased from 36.65 at baseline to 16.47 at day 30 ( p < 0.001). Reports of treatment responses submitted by owners and evaluation of CADESI-4 after treatment were significantly similar ( p < 0.001). Owners rated the response to treatment as good to excellent for 73,5% of the dogs. Adverse events, including vomiting, diarrhea, and/or lethargy, were observed in 18 dogs (17%). All events were transient, and none required treatment. Conclusions Based on findings in this study, lokivetmab was determined to provide a rapid and effective response for control of cAD. Lokivetmab was well tolerated with only mild and transient adverse events observed.